ClinicalTrials.gg
CompletedNCT01531322Updated Sep 7, 2018

A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Subjects

A Phase 1 interventional study of 13-valent Pneumococcal Conjugate Vaccine and 13-valent Pneumococcal Conjugate Vaccine in Pneumococcal Infection, sponsored by Pfizer. Completed at 2 sites in China. Open to participants aged 42 Days to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-09-07.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Non-randomized
Ages
42 Days to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections — none open to participants now, 1 under way, none of them phase 3. 13-valent pneumococcal vaccine · Pneumococcal Infections.

Enrollment
37th of 44
72 · median 328
Started
2011
with 2 others
Phase 1
6 of 44
none open now
Registered
15th of 44
by date
Lead sponsor
16 of 44
Pfizer

Among the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections, this one is the 37th largest by enrollment, is one of 3 that started in 2011, is one of 6 in phase 1, and was the 15th registered.

Pneumococcal Infections

298 studies on the registry are indexed under Pneumococcal Infections; 25 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

None of the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections is open now. The open studies under Pneumococcal Infections, anywhere →

About 13-valent pneumococcal vaccine

13-valent pneumococcal vaccine: first FDA approval 2010 (Prevnar 13). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 42 Days to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections as a file.
02

Study summary

This study will assess the safety and tolerability of a single dose of 13-valent Pneumococcal Conjugate Vaccine for approximately 1 month after vaccination sequentially in healthy Chinese adults aged 18 through 55 years, followed by children aged 3 through 5 years, and then infants aged approximately 2 months.

03

Conditions studied

  • Pneumococcal Infection

Keywords

  • 13vPnC
  • Healthy subjects
  • China
04

Who can participate

Ages eligible
42 Days to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age at the time of enrollment is:

    • 18 through 55 years (before the fifty sixth birthday) for Group 1.
    • 3 through 5 years (before the sixth birthday) for Group 2.
    • 42 to 98 days for Group 3.
  2. Healthy subject as determined by medical history, physical examination, and judgment of the investigator.

Exclusion criteria

Exclusion Criteria:

  • Previous vaccination with licensed or pneumococcal vaccine.
  • Previous anaphylactic reaction to any vaccine or vaccine-related component.
  • to vaccination with pneumococcal vaccine.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    Group 1

    Adults aged 18 through 55 years (before the fifty sixth birthday)

    Biological: 13-valent Pneumococcal Conjugate Vaccine

  • Experimental
    Group 2

    Children aged 3 through 5 years (before the sixth birthday)

    Biological: 13-valent Pneumococcal Conjugate Vaccine

  • Experimental
    Group 3

    Infants aged approximately 2 months (42 to 98 days)

    Biological: 13-valent Pneumococcal Conjugate Vaccine

Interventions

06

What researchers measure

Primary outcomes

  1. Number of participants reporting Adverse Events

    Time frame: Baseline to Month 1

07

Study locations

2 sites
  • Pfizer Investigational Site
    Huaian, Jiangsu 223300, China
  • Pfizer Investigational Site
    Nanjing, Jiangsu 210009, China
08

References and documents

Publications

  • Zhu F, Hu Y, Liang Q, Young M Jr, Zhou X, Chen Z, Liang JZ, Gruber WC, Scott DA. Safety and tolerability of 13-valent pneumococcal conjugate vaccine in healthy Chinese adults, children and infants. Ther Adv Drug Saf. 2015 Dec;6(6):206-11. doi: 10.1177/2042098615613985. PubMed 26668712 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2011, a primary completion of Jan 2012 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2011
First posted
Feb 10, 2012
Start
Oct 2011
Primary completionActual
Jan 2012
CompletionActual
Jan 2012
Last update
Sep 7, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 7, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01531322
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Feb 10, 2012
Start date
Oct 2011
Primary completion
Jan 2012
Completion
Jan 2012
Last update
Sep 7, 2018

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 13-valent pneumococcal vaccine

Start the discussion